CB213 / Crescendo Biologics - LARVOL DELTA

The multi-specific V-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. (PubMed, Br J Cancer) - "CB213 is poised to enter clinical development and, through intercepting both PD1 and LAG3 resistance mechanisms, may benefit patients with tumours escaping front-line immunological control."

Journal • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • LAG3 • PD-1 • PD-L1

[VIRTUAL] CB213: A half-life extended bispecific Humabody VH delivering dual checkpoint blockade to reverse the dysfunction of LAG3+PD-1+ double-positive T cells (AACR-II 2020) - "Humabody bispecific bound to PD1+LAG3- Jurkat cells with a lower EC50 compared to Nivolumab whereas binding to PD-1-LAG3+ Jurkat cells was equivalent to a benchmark anti-LAG3 mAb. Together these data support preclinical and clinical development of CB213, a novel 2:1 asymmetric Humabody dual checkpoint inhibitor targeting LAG3/PD-1 double positive dysfunctional T cells."

Checkpoint inhibition • IO Biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • CD8 • CTLA4 • IL2 • LAG3 • PD-1

Crescendo Biologics and Cancer Research UK sign Clinical development partnership to develop CB213, a novel bispecific humabody therapeutic (Businesswire) - "Crescendo Biologics Ltd...the world’s largest independent funder of cancer research, today announce a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody® immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need....Under the terms of the agreement, Cancer Research UK’s Centre for Drug Development will sponsor and fund a future Phase I clinical trial for CB213, in patients with solid tumours. Crescendo retains the right to further develop the CB213 immunotherapy programme, by licensing the results of the trial from Cancer Research UK for an undisclosed amount, success-based milestones and royalty payments." "

Licensing / partnership • New P1 trial • Oncology • Solid Tumor